Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Assets Average (2016 - 2026)

Intellia Therapeutics has reported Assets Average over the past 11 years, most recently at $800.5 million for Q1 2026.

  • Quarterly Assets Average fell 26.47% to $800.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $800.5 million through Mar 2026, down 26.47% year-over-year, with the annual reading at $1.0 billion for FY2025, 18.41% down from the prior year.
  • Assets Average was $800.5 million for Q1 2026 at Intellia Therapeutics, down from $883.7 million in the prior quarter.
  • Over five years, Assets Average peaked at $1.5 billion in Q1 2023 and troughed at $800.5 million in Q1 2026.
  • The 5-year median for Assets Average is $1.2 billion (2024), against an average of $1.2 billion.
  • Year-over-year, Assets Average soared 79.24% in 2022 and then dropped 26.47% in 2026.
  • A 5-year view of Assets Average shows it stood at $1.3 billion in 2022, then decreased by 2.31% to $1.3 billion in 2023, then fell by 7.07% to $1.2 billion in 2024, then fell by 25.25% to $883.7 million in 2025, then fell by 9.42% to $800.5 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Assets Average are $800.5 million (Q1 2026), $883.7 million (Q4 2025), and $912.1 million (Q3 2025).